Filing summary
Entity and period: The supplied filing is TenX Keane Acquisition’s Form 10-K for the fiscal year ended December 31, 2022, filed April 17, 2023. It is not a Citius Oncology, Inc. filing; the company name in the request does not match the filing.
Business context
TenX Keane is a blank-check company formed to pursue a business combination. It had no operating business, revenue, or identified target as of year-end. Its initial search focus was Asia, excluding targets based in or principally operating in mainland China, Hong Kong, or Macau. It completed its IPO on October 18, 2022.
Financial results and liquidity
| Metric | 2022 | Prior comparable period |
|---|---|---|
| Revenue | None | None |
| General and administrative costs | $138,115 | $10,113 |
| Trust investment income | $493,020 | None |
| Change in derivative liability | $25,906 income | None |
| Net income (loss) | $380,811 | $(10,113) |
| Cash at year-end | $289,175 | None |
| Trust investments at year-end | $67,813,020 | None |
The prior period is March 1, 2021 (inception) through December 31, 2021, not a full fiscal year. Basic and diluted earnings per share were $0.12 in 2022 versus a loss of $0.01 in the inception period. The 2022 profit was driven by trust investment income, not operating activity.
Cash used in operations was $47,968; cash used in investing was $67.32 million, principally the trust deposit; and financing provided $67.66 million. The company reported no long-term debt or other long-term contractual obligations. A sponsor promissory note of up to $300,000 was available, with no year-end balance outstanding; a new non-interest-bearing sponsor note was issued on April 14, 2023.
The filing reports $67.813 million of redeemable shares as temporary equity. It does not report operating margins, given the absence of revenue. No dividend was paid, and none was expected before a business combination.
Changes, outlook, and key risks
- The October 2022 IPO raised $66.0 million gross; a concurrent private placement raised $3.94 million. The company placed $67.32 million in trust. IPO and related transaction costs were reported as $4.86 million.
- The company had until nine months after the IPO closing to complete a business combination, with up to three three-month extensions. Each extension required a $660,000 sponsor loan to the trust; the filing identifies July 18, 2023 as the deadline absent extension. Failure to complete a transaction would trigger redemption of public shares and liquidation.
- The auditor included a going-concern explanatory paragraph, citing substantial doubt because the company must complete a transaction within its limited combination period. The financial statements include no adjustments for the uncertainty.
- Management expected to fund search and transaction costs with cash outside trust and potential sponsor financing, but warned that costs, redemptions, or transaction size could require additional financing. There was no assurance financing or a transaction would be available.
- Risks include a short transaction timeline, potential creditor claims against trust assets, sponsor and management conflicts of interest, dilution and redemption risk, and regulatory or market risks related to a future non-U.S. target. The filing states the company had no specific target under consideration and no substantive target discussions.
- Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation, consistent with the company’s emerging-growth-company status.
Most important facts to verify
- Confirm the intended issuer: this filing is for TenX Keane Acquisition, not Citius Oncology, Inc.
- Verify whether TenX Keane extended its business-combination deadline, completed a transaction, or liquidated after the period covered by this filing.
- Reconcile share counts: the filing reports 8,941,000 ordinary shares outstanding as of April 17, 2023, while the year-end balance sheet presents 6,600,000 redeemable shares plus 2,416,000 other shares.
- Check subsequent filings for actual cash needs, sponsor borrowing, redemptions, trust balance changes, and any target or transaction announcements.